{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:45:13Z","timestamp":1768283113824,"version":"3.49.0"},"reference-count":16,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,11,26]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Clinically relevant imetelstat concentrations significantly inhibit CFU-MEG formation from MNCs of ET patients and reduce hTERT expression. However, similar concentrations of imetelstat do not inhibit cytokine-induced CFU-MEG from MNCs of healthy donors.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000167","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T12:27:59Z","timestamp":1574771279000},"page":"3724-3728","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Imetelstat inhibits growth of megakaryocyte colony-forming units from patients with essential thrombocythemia"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-746X","authenticated-orcid":false,"given":"Gabriela M.","family":"Baerlocher","sequence":"first","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, and"},{"name":"Laboratory for Hematopoiesis and Molecular Genetics, Department of BioMedical Research, University of Bern, Bern, Switzerland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Haubitz","sequence":"additional","affiliation":[{"name":"Laboratory for Hematopoiesis and Molecular Genetics, Department of BioMedical Research, University of Bern, Bern, Switzerland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Braschler","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, and"},{"name":"Department of Hematology, Luzerner Kantonsspital, Lucerne, Switzerland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Brunold","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Burington","sequence":"additional","affiliation":[{"name":"Geron Corporation, Menlo Park, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Oppliger Leibundgut","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, and"},{"name":"Laboratory for Hematopoiesis and Molecular Genetics, Department of BioMedical Research, University of Bern, Bern, Switzerland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Go","sequence":"additional","affiliation":[{"name":"Geron Corporation, Menlo Park, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2019,11,26]]},"reference":[{"issue":"6","key":"2019112611383710600_B1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.semcancer.2011.10.001","article-title":"Role of telomeres and telomerase in cancer","volume":"21","author":"Shay","year":"2011","journal-title":"Semin Cancer Biol"},{"issue":"34","key":"2019112611383710600_B2","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1038\/s41388-019-0872-9","article-title":"Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players","volume":"38","author":"Yuan","year":"2019","journal-title":"Oncogene"},{"key":"2019112611383710600_B3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fgene.2016.00083","article-title":"Regulation of the telomerase reverse transcriptase subunit through epigenetic mechanisms","volume":"7","author":"Lewis","year":"2016","journal-title":"Front Genet"},{"issue":"5193","key":"2019112611383710600_B4","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1126\/science.7605428","article-title":"Specific association of human telomerase activity with immortal cells and cancer","volume":"266","author":"Kim","year":"1994","journal-title":"Science"},{"issue":"14","key":"2019112611383710600_B5","first-page":"3931","article-title":"A novel telomerase template antagonist (GRN163) as a potential anticancer agent","volume":"63","author":"Asai","year":"2003","journal-title":"Cancer Res"},{"issue":"33","key":"2019112611383710600_B6","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1038\/sj.onc.1208760","article-title":"Lipid modification of GRN163, an N3\u2032-->P5\u2032 thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition","volume":"24","author":"Herbert","year":"2005","journal-title":"Oncogene"},{"issue":"10","key":"2019112611383710600_B7","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1056\/NEJMoa1503479","article-title":"Telomerase inhibitor imetelstat in patients with essential thrombocythemia","volume":"373","author":"Baerlocher","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"2019112611383710600_B8","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"2019112611383710600_B9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/jcp.2007.054353","article-title":"Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis","volume":"62","author":"Florena","year":"2009","journal-title":"J Clin Pathol"},{"issue":"5","key":"2019112611383710600_B10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.leukres.2003.09.006","article-title":"Different expression levels of the telomerase catalytic subunit hTERT in myeloproliferative and myelodysplastic diseases","volume":"28","author":"Bock","year":"2004","journal-title":"Leuk Res"},{"issue":"20","key":"2019112611383710600_B11","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2019112611383710600_B12","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/leu.2008.81","article-title":"Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo","volume":"22","author":"Shammas","year":"2008","journal-title":"Leukemia"},{"issue":"13","key":"2019112611383710600_B13","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/nar\/25.13.2595","article-title":"Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP)","volume":"25","author":"Kim","year":"1997","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"2019112611383710600_B14","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.leukres.2014.04.008","article-title":"Telomerase, hTERT and splice variants in patients with myelodysplastic syndromes","volume":"38","author":"Dong","year":"2014","journal-title":"Leuk Res"},{"key":"2019112611383710600_B15","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/01.HS9.0000561628.96745.54","article-title":"Treatment with imetelstat provides durable transfusion independence (TI) in heavily transfused non-del(5q) lower risk MDS (LR-MDS) relapsed\/refractory (R\/R) to erythropoiesis stimulating agents (ESAS)","volume":"3","author":"Fenaux","year":"2019","journal-title":"HemaSphere"},{"issue":"11","key":"2019112611383710600_B16","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1038\/leu.2017.78","article-title":"Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis","volume":"31","author":"Mosoyan","year":"2017","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/22\/3724\/1543387\/advancesadv2019000167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/22\/3724\/1543387\/advancesadv2019000167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T12:28:06Z","timestamp":1574771286000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/22\/3724\/428879\/Imetelstat-inhibits-growth-of-megakaryocyte"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,26]]},"references-count":16,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019,11,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000167","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,26]]}}}